Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
ConclusionThese findings support adjusting the 300 mg niraparib starting dose to 200 mg QD in patients with MHI.Trial registrationNCT03359850; registered December 2, 2017
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Study | Thrombocytopenia